Kucukgoz Gulec Umran, Gumurdulu Derya, Guzel Ahmet Baris, Paydas Semra, Seydaoglu Gulsah, Acikalin Arbil, Khatib Ghanim, Zeren Handan, Vardar Mehmet Ali, Altintas Aytekin
Department of Obstetrics and Gynecology, Faculty of Medicine, Cukurova University, 01330, Adana, Turkey,
Arch Gynecol Obstet. 2014 Feb;289(2):393-8. doi: 10.1007/s00404-013-3000-z. Epub 2013 Aug 22.
Stage, tumor grade and histological subtype determine the clinical behavior in ovarian tumors. Some additional factors are related to tumor cell biology and are the useful predictors for identifying the patients with poor prognosis. The aim of this study is to evaluate the prognostic significance of survivin, Ki-67 and Topoisomerase IIα (TOPO IIα) in epithelial ovarian cancer (EOC).
Seventy-three patients with EOC were included in this study. Survivin, Ki-67 and TOPO IIα expressions were studied by immunohistochemistry on formalin-fixed, paraffin-embedded tissue sections. Nuclear staining for all antibodies was scored on a three-tiered system and more than 10 % staining was accepted as expression. The relationship between the expressions of survivin, Ki-67, TOPO IIα and clinicopathological parameters including age, stage, grade, platinum resistance and survival was evaluated.
Survivin, Ki-67 and TOPO IIα expressions were found in 20, 82 and 86 % of the tumors, respectively. Ki-67 and TOPO IIα expressions were found to be related to poor overall survival (p = 0.005, 0.004, respectively), while survivin expression was not associated with overall survival. There was no association between TOPO IIα and Ki-67 expressions and histological subtype, stage or grade. However, we found an important relationship between TOPO IIα expression and platinum resistance (p = 0.044). Platinum resistance was found to be an independent prognostic factor in EOC.
Ki-67 and TOPO IIα expressions were found to be related to poor overall survival, and TOPO IIα expression was found to be associated with platinum resistance.
分期、肿瘤分级和组织学亚型决定卵巢肿瘤的临床行为。一些其他因素与肿瘤细胞生物学相关，是识别预后不良患者的有用预测指标。本研究的目的是评估生存素、Ki-67和拓扑异构酶IIα（TOPO IIα）在上皮性卵巢癌（EOC）中的预后意义。
本研究纳入73例EOC患者。采用免疫组织化学方法在福尔马林固定、石蜡包埋的组织切片上研究生存素、Ki-67和TOPO IIα的表达。所有抗体的核染色采用三级评分系统，超过10%的染色被视为表达。评估生存素、Ki-67、TOPO IIα的表达与包括年龄、分期、分级、铂耐药性和生存率在内的临床病理参数之间的关系。
分别在20%、82%和86%的肿瘤中发现生存素、Ki-67和TOPO IIα的表达。发现Ki-67和TOPO IIα的表达与总体生存率差有关（分别为p = 0.005、0.004），而生存素的表达与总体生存率无关。TOPO IIα和Ki-67的表达与组织学亚型、分期或分级之间无关联。然而，我们发现TOPO IIα的表达与铂耐药性之间存在重要关系（p = 0.044）。铂耐药性被发现是EOC的一个独立预后因素。
发现Ki-67和TOPO IIα的表达与总体生存率差有关，且TOPO IIα的表达与铂耐药性有关。
